MX2020004305A - Linea celular eucariota. - Google Patents

Linea celular eucariota.

Info

Publication number
MX2020004305A
MX2020004305A MX2020004305A MX2020004305A MX2020004305A MX 2020004305 A MX2020004305 A MX 2020004305A MX 2020004305 A MX2020004305 A MX 2020004305A MX 2020004305 A MX2020004305 A MX 2020004305A MX 2020004305 A MX2020004305 A MX 2020004305A
Authority
MX
Mexico
Prior art keywords
cell line
eukaryotic cell
relates
present
viral particles
Prior art date
Application number
MX2020004305A
Other languages
English (en)
Inventor
Alfredo Nicosia
Stefano Colloca
Original Assignee
Nouscom Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nouscom Ag filed Critical Nouscom Ag
Publication of MX2020004305A publication Critical patent/MX2020004305A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
    • C12N2830/006—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB tet repressible
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gynecology & Obstetrics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Reproductive Health (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a una línea celular, uso de la línea celular y un método para producir partículas virales infecciosas usando dicha línea celular.
MX2020004305A 2017-10-25 2018-10-25 Linea celular eucariota. MX2020004305A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17198339 2017-10-25
PCT/EP2018/079341 WO2019081673A1 (en) 2017-10-25 2018-10-25 LINE OF EUKARYOTIC CELLS

Publications (1)

Publication Number Publication Date
MX2020004305A true MX2020004305A (es) 2020-11-11

Family

ID=60182488

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004305A MX2020004305A (es) 2017-10-25 2018-10-25 Linea celular eucariota.

Country Status (12)

Country Link
US (1) US11643666B2 (es)
EP (1) EP3700560A1 (es)
JP (1) JP7274225B2 (es)
KR (1) KR102688005B1 (es)
CN (1) CN111386126B (es)
AU (1) AU2018356538B2 (es)
BR (1) BR112020007772A2 (es)
CA (1) CA3076026C (es)
IL (1) IL274191A (es)
MX (1) MX2020004305A (es)
SG (1) SG11202003609VA (es)
WO (1) WO2019081673A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202323529A (zh) 2021-10-18 2023-06-16 美商再生元醫藥公司 包括腺病毒相關病毒聚核苷酸的真核細胞
WO2024126795A1 (en) * 2022-12-15 2024-06-20 Universite De Namur Apobec-deficient cells for adenoviral vector production
WO2026041811A1 (en) 2024-08-23 2026-02-26 Transgene Recombinant poxvirus and method for regulating the expression of toxic conditional gene products of said recombinant poxvirus in a producing cell
WO2026047314A1 (en) * 2024-08-28 2026-03-05 University Of Surrey Recombinant vector

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464758A (en) * 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
AU746850B2 (en) * 1994-07-01 2002-05-02 Tet Systems Holding Gmbh & Co. Kg Tetracycline-regulated transcriptional modulaters
CA2244412A1 (en) * 1996-01-26 1997-07-31 Hsc Research And Development Limited Partnership Nucleic acids and proteins related to alzheimer's disease, and uses therefor
CN1880457B (zh) * 2001-10-11 2010-05-26 麦克公司 Ad6重组核酸
KR20030032443A (ko) * 2001-10-18 2003-04-26 백순영 테트라사이클린 유도성 ｈｉｖ-1 패키징 세포주 및 이를이용한 ｈｉｖ-1 ｄｉ 입자의 생산방법
US6835568B2 (en) * 2001-10-30 2004-12-28 Virxsys Corporation Regulated nucleic acid expression system
DE10360483B4 (de) * 2003-12-22 2007-11-15 Scil Proteins Gmbh Expressionsvektor und dessen Verwendung
DE602005017743D1 (de) * 2004-01-23 2009-12-31 Angeletti P Ist Richerche Bio Impfstoffträger für schimpansen-adenovirus
EP1809753A1 (en) * 2004-11-02 2007-07-25 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Adenoviral amplicon and producer cells for the production of replication-defective adenoviral vectors, methods of preparation and use thereof
JP2008104357A (ja) 2005-02-09 2008-05-08 Banyu Pharmaceut Co Ltd ＴｅｔＲ発現非ヒトトランスジェニック動物及びその製造方法
EP1935978A4 (en) 2005-09-15 2009-01-07 Japan Science & Tech Agency PROCESS FOR CONTROLLING PROTEIN REMOVAL BY TETRACYCLIN ANTIBIOTICUM
US20070122880A1 (en) * 2005-10-19 2007-05-31 Institut Curie Vector for the inducible expression of gene sequences
WO2007073513A2 (en) * 2005-11-10 2007-06-28 Genvec, Inc. Method for propagating adenoviral vectors encoding inhibitory gene products
JP2009519715A (ja) * 2005-12-16 2009-05-21 ザ ユーエービー リサーチ ファウンデーション ウイルスベクターを使用する制御された遺伝子発現に関する組成物および方法
AU2009260593A1 (en) * 2008-05-28 2009-12-23 Oregon Health & Science University Methods of identifying inhibitors of gene silencing in mammalian cells
DK2195013T3 (da) * 2008-07-24 2012-02-06 Nsgene As Terapeutisk anvendelse af en vækstfaktor, METRNL
AU2016244220B2 (en) * 2008-12-23 2018-05-17 Amgen Inc. Human CGRP receptor binding proteins
WO2011025717A2 (en) * 2009-08-31 2011-03-03 The Brigham And Women's Hospital, Inc. Promoter system for regulatable gene expression in mammalian cells
WO2011126370A1 (en) * 2010-04-09 2011-10-13 Universiteit Utrecht Holding B.V. Recombinant multimeric influenza proteins
CN102311973A (zh) * 2010-07-05 2012-01-11 北京五加和分子医学研究所有限公司 一种新型miRNA和编码蛋白基因共表达载体
CN102344903B (zh) * 2010-07-29 2012-11-28 首都医科大学附属北京友谊医院 成体大鼠肝脏卵圆细胞系及其用途
DK2618839T3 (en) * 2010-09-20 2018-08-06 Stichting Wageningen Res PROCEDURES FOR THE MANUFACTURE OF BUNYAVIRUS REPLICATOR PARTICLES
WO2012089231A1 (en) * 2010-12-30 2012-07-05 Okairòs Ag Paramyxovirus vaccines
CN102747096B (zh) * 2011-04-18 2015-04-08 中国医学科学院基础医学研究所 基因搜寻载体、随机基因突变调控方法及用途
KR101427200B1 (ko) * 2011-11-24 2014-08-07 주식회사 바이로메드 아데노바이러스 생산 신규 세포주 및 그의 용도
WO2014005643A1 (en) * 2012-07-05 2014-01-09 Okairos Ag Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
CN103820392A (zh) * 2012-11-18 2014-05-28 复旦大学附属华山医院 基于HepG2 HBV rtS202G ETV耐药变异株细胞系及其建立方法
AU2015218909A1 (en) * 2014-02-19 2016-08-04 Emergent Biosolutions Canada Inc. Marburg monoclonal antibodies
CN104212802B (zh) * 2014-09-25 2017-09-12 中国人民解放军第二军医大学东方肝胆外科医院 一种肿瘤细胞广谱高活性启动子及其用途
GB2540786A (en) * 2015-07-28 2017-02-01 Glaxosmithkline Ip Dev Ltd Codon optimised tet repressor proteins
WO2017152042A2 (en) * 2016-03-04 2017-09-08 New York University Virus vectors expressing multiple epitopes of tumor associated antigens for inducing antitumor immunity
US11185555B2 (en) * 2016-04-11 2021-11-30 Noah James Harrison Method to kill pathogenic microbes in a patient
CN107058387B (zh) * 2017-04-13 2019-09-06 新乡医学院 一种适合hek293细胞的双顺反子表达载体及其制备方法、表达系统、应用
WO2018213353A1 (en) * 2017-05-16 2018-11-22 Cairn Biosciences, Inc. Multiplex assay

Also Published As

Publication number Publication date
BR112020007772A2 (pt) 2020-10-06
CN111386126B (zh) 2024-01-30
WO2019081673A1 (en) 2019-05-02
JP2021500011A (ja) 2021-01-07
IL274191A (en) 2020-06-30
AU2018356538A1 (en) 2020-05-14
CN111386126A (zh) 2020-07-07
KR102688005B1 (ko) 2024-07-25
JP7274225B2 (ja) 2023-05-16
RU2020114699A (ru) 2021-11-25
SG11202003609VA (en) 2020-05-28
AU2018356538B2 (en) 2023-09-28
CA3076026A1 (en) 2019-05-02
EP3700560A1 (en) 2020-09-02
NZ763879A (en) 2025-03-28
US11643666B2 (en) 2023-05-09
RU2020114699A3 (es) 2021-11-25
US20200308601A1 (en) 2020-10-01
CA3076026C (en) 2024-10-01
KR20200101322A (ko) 2020-08-27

Similar Documents

Publication Publication Date Title
CO2020006900A2 (es) Medios y método para preparar vectores virales y usos de los mismos
CL2019000424A1 (es) Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos.
AU2018335389A1 (en) Nanofiber structures and methods of use thereof
MX2019003406A (es) Estructuras de nonofibra y metodos de uso de las mismas.
MX2021004479A (es) Agentes biologicos y su uso en plantas.
CL2016002455A1 (es) Anticuerpos multiespecíficos.
MX374788B (es) Anticuerpos anti-tim3 y metodos de uso.
MX386587B (es) ANTICUERPOS ANTI-CD79b Y MÉTODOS DE USO.
ECSP18007905A (es) Anticuerpos monoclonales contra bcma
EP4335874A3 (en) Anti-hla-g antibodies and use thereof
CL2018000302A1 (es) Proteínas de fusión de factor ix y métodos para producirlas y utilizarlas
MX2019007021A (es) Anticuerpos il-11ra.
ECSP20021132A (es) Enantiómeros de tiazoles sustituidos compuestos antivirales
MX372675B (es) Anticuerpos anti-jagged1 y metodos de uso.
MX382518B (es) Antigenos de citomegalovirus y su uso.
CR20180605A (es) Anticuerpos anti-cd40 y sus usos
AR119997A1 (es) Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5 / klk7 y métodos de uso
MX2016001169A (es) Mezcla de cemento que incluye polimeros.
TR201900124T4 (tr) Dispersiyon Reçineleri
MX372963B (es) Reordenamiento del virus de influenza b.
MX2016004853A (es) Metodos de uso de anticuerpos anti-ly6e.
MX2020004305A (es) Linea celular eucariota.
CR20150369A (es) Método para preparar fideos instantáneos, composición de harina para fideos instantáneos y uso de la misma
MX2019010492A (es) Kits y metodos para preparar composiciones de plaquetas con patogeno inactivado.
MX2019000246A (es) Formas en estado solido del dimesilato de palbociclib.